The purpose of the Administration, Communication, and Planning Core is to assure the coordination of the Dana Farber/Harvard Cancer Center (DF/HCC) Myeloma SPORE components and to provide oversight and leadership of the scientific, administrative, and fiscal aspects of the SPORE. The SPORE Directors will oversee the administrative coordination of the various clinical and laboratory studies outlined in this Program. They will integrate scientific and clinical efforts within and between Projects, and assure the translation of laboratory findings to the bedside;and conversely, the initiation of laboratory studies stemming from clinical observations. During the prior funding period, the infrastructure has been created to have seamless communication and exchange of data between SPORE sites, facilitating collaborative preclinical studies and clinical trials. Multiple joint publications, completed and ongoing clinical trials, and the translation of several novel targeted therapies from bench to bedside confirm the communication and integration of our efforts. This Core will continue to facilitate exchange of information among the SPORE members, as well as the internal and external advisory committees. It will provide clinical research nursing support for the proposed clinical trials. In addition, as in the previous funding period, a clinical study coordinator will assure appropriate sample acquisition and trafficking. The grants administrator will allocate resources in a timely and integrated fashion to facilitate successful completion of the proposed studies.
The Specific Aims of the Administration, Communication, and Planning Core are as follows: 1. To monitor research progress and plan for the future 2. To foster collaborative research within the SPORE and between SPOREs 3. To integrate the Myeloma SPORE into the DF/HCC structure 4. To provide necessary resources and fiscal oversight 5. To promote rapid dissemination of significant research findings

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA100707-11A1
Application #
8607274
Study Section
Special Emphasis Panel (ZCA1-RPRB-0 (O1))
Project Start
2003-09-01
Project End
2018-08-31
Budget Start
2013-09-18
Budget End
2014-08-31
Support Year
11
Fiscal Year
2013
Total Cost
$242,200
Indirect Cost
$94,323
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Hu, Y; Song, W; Cirstea, D et al. (2015) CSNK1?1 mediates malignant plasma cell survival. Leukemia 29:474-82
Bae, J; Prabhala, R; Voskertchian, A et al. (2015) A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients. Leukemia 29:218-29
Suzuki, R; Hideshima, T; Mimura, N et al. (2015) Anti-tumor activities of selective HSP90?/? inhibitor, TAS-116, in combination with bortezomib in multiple myeloma. Leukemia 29:510-4
Campigotto, Federico; Weller, Edie (2014) Impact of informative censoring on the Kaplan-Meier estimate of progression-free survival in phase II clinical trials. J Clin Oncol 32:3068-74
Hideshima, T; Mazitschek, R; Santo, L et al. (2014) Induction of differential apoptotic pathways in multiple myeloma cells by class-selective histone deacetylase inhibitors. Leukemia 28:457-60
Greenberg, A J; Rajkumar, S V; Therneau, T M et al. (2014) Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma. Leukemia 28:398-403
Lohr, Jens G; Adalsteinsson, Viktor A; Cibulskis, Kristian et al. (2014) Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol 32:479-84
Anderson, K K; Flora, N; Archie, S et al. (2014) A meta-analysis of ethnic differences in pathways to care at the first episode of psychosis. Acta Psychiatr Scand 130:257-68
Landgren, O; Graubard, B I; Katzmann, J A et al. (2014) Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey. Leukemia 28:1537-42
Yin, Li; Kufe, Turner; Avigan, David et al. (2014) Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell death. Blood 123:2997-3006

Showing the most recent 10 out of 184 publications